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ABSTRACT
The preoperative (neoadjuvant) setting of breast cancer treatment is an optimal in vivo model by which to 
allow the characterization of  biomarker expression pattern with the tumor remaining in situ throughout 
treatment as an in vivo measure of  response to particular therapy. Elucidating surrogate molecular or 
cellular markers of tumor response to therapy, may provide biological insight into both, the mechanism 
of tumor growth dynamics and drug sensitivity/resistance. Owing to the knowledge that many drugs are 
effective on actively proliferating cells and more intriguingly, that many anticancer agents with differing 
modes of action achieve cytotoxic effects by inducing apoptosis, has lead to a reappraisal of traditional 
views of tumor response/resistance to cytotoxic drugs in vivo. Accordingly, this review article will focus 
on discussing apoptosis phenomena and the p53 and bcl-2 protein as its regulators of principal impor-
tance; a cell proliferation determined by the Ki-67 expression, as the major counterbalancing process to 
apoptosis is also considered. This paper reviews the rationale for the use of these proteins as indices of 
tumor response to therapy, as well as the published literature regarding their clinical relevance. So far, 
no firm conclusions can be made concerning their predictive utility.
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INTRODUCTION
T
he scenario of presurgical therapy of breast cancer within neoadjuvant setting has 
been proposed as an ideal in vivo model for studying the tumor biological features 
WKDWPLJKWEHUHOLDEOHPDUNHUVIRUWKHDVVHVVPHQWRIWXPRUUHVSRQVHWRWKHUDS\DQGRU
valuable indices for long-term disease outcome. After exposure to a cytotoxic agent in
vitro, a single cell will survive (with or without a temporary growth arrest) or die. Thus, 
sensitivity and resistance should be defined as mutually exclusive states. However, the in
vivo situation differs because cell populations are heterogeneous (1). Therefore, the use of 
primary (neoadjuvant) chemotherapy offers the opportunity to test clinical relevance of the 
pattern of modifications in the cell phenotype induced by therapy with the tumor remaining 
in situ throughout treatment as an in vivo measure of response. In addition, testing could 
be done on intact human breast tissue, with vasculature, stroma, and other components, 
conditions that cannot be replicated in laboratory experiments. This treatment modality 
allows for accurate tumor measurements and assessment of objective tumor response by 
use of well-defined response criteria; furthermore, the response of macroscopic tumors 
could be assessed at the cellular level. In addition, serial determinations of intratumoral 
characteristics, due to available samples throughout treatment, can be obtained, allowing 
for comparison of biological features before and after therapy. Accordingly, the neoadju-
vant clinical setting has been increasingly evaluated as an optimal study designed for the 
determination of breast cancer biological features, and the significance of their expression 
pattern as well as possible variations induced by therapy, to address the reliability of these 
ELRPDUNHUVDVSURJQRVWLFSUHGLFWLYHIDFWRUV,QDQDGYDQFHHOXFLGDWLQJVXUURJDWHPROHFXODU
or cellular markers of tumor response to therapy, may provide, earlier biological insight into 
ERWKWKHPHFKDQLVPRIWXPRUJURZWKDQGGUXJVHQVLWLYLW\UHVLVWDQFH
RATIONALES FOR THE HYPOTHESIS OF PREDICTIVE VALUES OF 
APOPTOSIS PHENOMENA, p53, bcl-2 AND Ki-67 IN BREAST CANCER
Tumor growth is the net result of deregulated cell proliferation in relation to cell death, in 
the form of apoptosis, as the key determinants of cancer growth dynamics and kinetic cell 
activity (3). These observations were highlighted the new insight into the tumor growth 
control. Furthermore, the proliferation kinetics and apoptosis pathway are so far considered 
as the most relevant biological phenomena that are associated with cellular effects induced 
in vivo by chemotherapy. Owing to the knowledge that many drugs are effective on actively 
proliferating cells (4) and more intriguingly, laboratory evidence which have shown that 
many anticancer agents with differing modes of action achieve cytotoxic effects, at least 
partly, by inducing apoptosis (5), has led to a reappraisal of traditional views of tumor 
response and resistance to cytotoxic drugs. Since the mechanism that disturbed apoptosis 
may be relevant in development of intrinsic or acquired resistance to cytotoxic drugs (6), 
of the factors controlling and regulating this complex phenomenon, the bcl-2 and p53 as 
prototype apoptotic markers, are considered of principal importance, in common with the 
Ki-67 as indicator of proliferation, which is the main counterbalancing process to apoptosis 
in tumor growth dynamics.
Apoptosis
Apoptosis is a physiological mechanism of an actively regulated cellular process that leads 
to destruction of individual cells, and is characterized by distinct morphological features (7). 
Of the factors controlling and regulating this complex phenomenon, the p53 and bcl-2 as 
the prototype protein of the bcl-2 gene family, are considered of principal relevance.
Biochemically, the end result of this complex phenomenon is DNA fragmentation by endo-
nucleases and nuclear destruction, which are mediated by a family of proteases, caspases, 
which participate in the induction and execution of the apoptotic process (8).
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Despite the multitude of intracellular targets for the different triggers of apoptosis, many 
of antineoplastic agents induce apoptosis in susceptible cells through the activation of 
a few common pathways (9). Two separable pathways, leading to caspase activation, 
have been characterized. The extrinsic, receptor-mediated killing involves members of 
71)VXSHUIDPLO\ZLWKWKHEHVWNQRZQSDUWLFLSDQWLQDSRSWRVLV²)DV$SR&'71)
and TRAIL (Apo-2) receptors that activate activator caspase -8, and -10 which in turn 
activate effectors caspases-3 and -7. The second, well characterized intrinsic pathway 
(mitochondria-mediated killing) requires disruption of the mitochondrial membrane and 
release of cytochrome-c, (and other proteins) which is involved in the formation of the 
apoptosome complex (cyt c, Apaf-1, pro-caspase-9) leading to activation of caspase-9 
that subsequently activates caspase-3.
Bcl-2
The intrinsic apoptotic pathway is dominated by the Bcl-2 family of proteins (10), which 
governs mitochondrial membrane permeabilisation by the opposing actions of pro- and 
antiapoptotic bcl-2 family members. These proteins may interact physically with each other 
trough a network of homo- and heterodimers, the relative proportions of which ultimately 
control the sensitivity or resistance of cells to apoptotic stimuli. Family members are clas-
sified on the basis of structural similarity to the bcl-2 homology (BH) domains, with main 
BH3 domain that is essential for heterodimerisation among members, and constitutes the 
minimum domain required for the proapoptotic function. The bcl-2 family is devisable into 
three classes: prosurvival-antiapoptotic, whose members are most structurally similar 
to bcl-2 ( such as bcl-xl); pro-apoptotic proteins (Bax, Bak), that antagonize prosurvival 
functions of bcl-2: and the pro-apoptotic “ BH3-only” proteins. Proapoptotic bcl-2 proteins 
(Bax and Bak) can be activated directly following interaction with Bid (BH3-only protein). 
Alternatively, binding of other BH3-only proteins (Noxa, Puma, Bad, Bim) to antiapoptotic 
proteins (notably bcl-2 and bcl-xl) results in activation of Bax and Bak., thus promoting 
apoptosis (11). An important regulatory factor in many cells is the balance between 
concentrations of Bax and bcl-2 proteins. Since bcl-2 may heterodimerize with Bax , its 
increased expression leads to formation of their heterodimers, thereby shift a balance 
which favor abrogation of apoptosis. In line with their antiapoptotic function, bcl-2 inhibit 
the release of cytochrome c or Apaf-1 from mitochondria, keeping cells alive by prevent-
ing caspase activation. It is ascertained that there is considerable cross-talk between the 
extrinsic and intrinsic pathway. 
In vitro studies suggest that bcl-2 may contribute to resistance to a series of cytotoxic 
drugs in breast cancer and that some combination of agents resulted in reduced bcl-2 
expression; therefore the degree of bcl-2 expression may somewhat contribute to the level 
of resistance to chemotherapy.  
S
A sensor of cellular stress, p53 is a critical initiator of the intrinsic apoptotic pathway, 
though it appears that p53 can function as a master regulator of the apoptotic program, 
capable of coordinating the process at multiple levels via several mechanisms (12). 
The role of p53 protein as a multifunctional transcriptional regulator is to maintain genomic 
VWDELOLW\WKURXJKLWVSDUWLFLSDWLRQLQWKHFHOOF\FOHUHJXODWLRQDW*DQGRU*SKDVH
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PHGLDWHGDWOHDVWLQ
part by p21), followed by DNA repair (gadd-45, PCNA). In cells where p53 activation pre-
dominantly stimulates this effect (rather than apoptosis) p53 would function as a survival 
gene, and its loss would be expected to sensitize the cell to genotoxic stress (14). However, 
being a key player in apoptosis induction, which is a desirable goal of different treatment 
approaches, p53 activity is thought to be a crucial predictor of their effectiveness (15). This 
assumption is largely based on some laboratory evidence that observed that alteration in 
TP53 gene function (p53 is its encoded protein)  predict for resistance to chemotherapy, 
both in vitro (16) and animal in vivo (17). This finding has lead to the merging investigation 
of the p53 function in relation to the different treatment -induced effects (18).
Intriguingly, a key subset of the bcl-2 family genes are p53 targets (9,12). P53 can initiate 
apoptosis by transcriptionally activating proapoptotic bcl-2 gene family (Bax, Bak, Noxa,   
and PUMA) and repressing antiapoptotic bcl-2 proteins (bcl-2, bcl-xl) and IAPs proteins 
which inhibit  caspase  activity. One pathway of apoptosis induction by p53 is through 
its transcriptional activation of  the enigmatic bax gene in the context of PUMA that is 
also directly induced by p53 in response to DNA damage. PUMA expression promotes 
mitochondrial translocation and dimerization of Bax, thus culminating in apoptosis induc-
tion. Bax is absolutely required for PUMA-mediated apoptosis, and participates in death 
response as an indirect target of p53 through PUMA. Thus, it appears that, in response to 
DNA damage, p53 activates the intrinsic mitochondrial apoptotic pathway (12,19). P53, 
also, promotes cytochrome c release through induction of target genes encoding BH-3 
only proteins, and Apaf-1 expression, thus mediating the apoptosome complex activation. 
7KHH[WULQVLFDSRSWRWLFSDWKZD\GUXJLQGXFHGVXLFLGHPHGLDWHGE\)DV&'H[SUHVVLRQ
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which is mainly cell-type specific. It is also obvious that certain therapies may also induce 
apoptosis via a p53-independent pathway (9,14,19).
So, p53 modulates treatment responsiveness, but the criteria that influence p53 to stimulate 
cell cycle arrest or apoptosis are only partially understood. The summation of the type of 
stress signals, p53 expression levels, and the cell type in particular cellular context, are 
general factors that influence the net result of altering p53 status. These alternative scenario 
of protective versus sensitizing roles of p53 status, also raises the important notion that 
p53 may do so in opposite directions for different drugs or treatments, that are applied  on 
the different cellular context, that is, cell cycle phase, state of differentiation, and others, 
associated molecular aberrations being most relevant. Presumably, the key to predicting the 
consequence of p53 loss lies in understanding which p53-dependent action is the dominant 
output of a specific treatment in a given cell (9,14). 
Ki-67
Another major area in a breast cancer research is the process of cell proliferation that takes 
place through a defined process in which several phases can be recognized rendering 
the concept of cell cycle (20). Many studies evaluating the role of individual genes and 
factors regulating these processes, has been attempted, but the functional end result of 
this process -a cell dividing– has remained the most important factor so far. An optimal 
assessment of proliferation rate of a tumor includes measurements of the growth fraction, 
in addition to cell cycle time (21). The different methods to assess proliferation have been 
available, and it is proposed that the growth fraction of tumor cells could be easily measured 
by means of immunohistochemistry (22). The expression of Ki-67 protein throughout the 
cell cycle in proliferating cells and their absence in quiescent cells created interest on its 
potential role as a marker of cell proliferation (23). The cellular appearance and location of 
the Ki-67 protein throughout the cell cycle is not homogenous, with overall evidence that 
the levels of this protein are low during G1- and early S-phase and progressively increased 
to reach a maximum during mitosis. There is little known about essential function of Ki-67 
in active cycling cells. Apoptosis provides the major counterbalancing determinant of tumor 
growth to proliferation, and index based on the Ki-67 – apoptosis ratio might be crude 
indices of cell turnover or growth index (24).
The contribution of molecular markers to the prediction of response 
WRFKHPRWKHUDS\LQQHRDGMXYDQWVHWWLQJ$UHYLHZRIWKHOLWHUDWXUHRQ
DSRSWRVLV.LEFODQGS
It is beyond a scope of this article to consider an extensive literature about numerous 
biological markers that have been of interest of basic scientist and clinicians in the eluci-
dation of the cancer cell response to anticancer agents, as well as the published clinical 
correlative study addressing the use of each one to predict response to particular therapy 
in breast cancer patients. The determination of relevant predictive factors in breast cancer is 
an important issue to address, since knowledge of the expression patterns of these factors ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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is necessary in selecting the best option for further therapy. If the chemotherapy elicit bio-
marker phenotype changes their reliability might be reduced and their predictive value might 
be uncertain, and one has to raise the question whether these factors should be determined 
in the tumor samples prior to chemotherapy or in excised tumor after therapy. 
So far there have been a paucity of studies examining the issue of chemotherapy induced 
apoptotic phenomena in a human solid tumor, notably in patients with breast cancer. 
Rasbridge  et al. (25) first noted morphological changes including apoptosis, which were 
induced by neoadjuvant therapy and found variable response pattern. Chemotherapy-
induced histologic changes in neoplastic tissue ranged from nuclear and cytoplasmic 
alteration to stromal degeneration and fibrosis, which are not uniformly present throughout 
the tumor, and correlate with pathologic tumor response (26). It is a more difficult to 
recognize and quantify apoptosis in solid tissues for several reasons. Apoptosis itself is 
relatively rapid process and most of apoptotic cells are efficiently removed from a tissue by 
phagocytic elements, thus escaping detection. Cancer tissue undergo additional changes, 
VXFKDVPXWDWLRQDQGRUDEQRUPDOH[SUHVVLRQRIFULWLFDOGHDWKUHJXODWLQJJHQHVZKLFKPD\
greatly reduced apoptosis, as well as altered interactions with the surrounding extracellular 
matrix. Other biological properties, such as proliferation rate and the growth fraction may 
also influence the rate of cell death in tumors. All these caveats may explain why there 
appears to be so few apoptotic cells in tumor tissue compared to physiologically active 
tissue or in vitro tumor cell systems. As central biochemical event of apoptosis is endo-
nucleolysis, which results in DNA cleavage into oligonucleosomal-sized fragments – DNA 
fragmentation, this, form the basis of TUNEL assay on histological sections, that has been 
a reproducible method to assess apoptotic cells in clinical samples (27).
It might be important and useful to compare apoptotic values of cancer specimens at 
different time-points during chemotherapy, because in this way we could distinguish the 
endogenous apoptotic activity in patient’s tumors from their apoptotic levels induced by the 
chemotherapy. In a pilot study by Ellis et al (28) it was shown a significant, more then 50 
% increase in the  apoptotic index (AI) in breast cancer biopsy following  24 hours after 
commencing treatment. The later published reports corroborated this findings of early 
induction of apoptosis within 24-48 hours after drug administration (29,30), or even later 
on 7 days (31). Moreover, in a several studies an obvious increase in apoptosis elicited by 
chemotherapy was observed in post-therapy specimens at the time of surgery (32,33,34). 
These corresponding findings related to the chemotherapy-induced increase in apoptotic 
activity of cancer samples following the various chemotherapy regimens, suggest that 
apoptosis is not restricted to a specific drugs but rather is valid for many drugs with dif-
ferent mechanism of action; and they might be conclusive evidence of an in vivo response
and pattern of modifications in cell phenotype induced by different agents (6,9). However, 
taken all together, these studies also revealed that the apoptotic index may have a different 
relevance in the estimation of objective response of breast cancer to chemotherapy; the 
increase in apoptosis levels accompanied by pronounced changes in its values during 
chemotherapy were significantly associated with greater pathological (30) or clinical 
(31,34) tumor response, or no correlation was seen (29). Besides, there was no found 
correlation either between pathological (30) or clinical response (34) to chemotherapy and 
pretreatment, baseline measurements of apoptosis levels; while post-chemotherapy AI cor-
related with clinical response and increased relapse and overall survival (32,33).Therefore, 
measurement of apoptosis warranted to confirm its clinical usefulness as a predictive 
biomarker in the larger collaboration studies.
In a line with the proposed hallmark of tumor growth dynamics that cell proliferation is the 
main counterbalancing determinant to apoptosis (24) a changes in tumor cell proliferation 
that are induced by chemotherapy have been evaluated in substantial number of correlative 
clinical studies. Proliferative activity in tumor cells has been suggested as a prognostic 
marker, but conflicting data have been presented on its predictive value. Several groups 
have found that Ki-67 index decreases after primary chemotherapy compared to its baseline 
pre-treatment values (34-37) but with various clinical relevance; tumors displaying more 
than  75% reduction were more likely to achieve a pathological response (36) or  high 
proliferation of tumor cells could be indicator of obtaining complete pathological response 
(35). Reduced proliferation in post-therapy tumor samples may reflect a direct effect of 
therapy on the cycling cells, with reduced proliferation in residual tumor cell population 
surviving therapy (28). Whereas most studies reported that high proliferation, the baseline 
level in pre-treatment samples, were related to objective tumor response, in some papers 
the finding of reduced Ki-67 expression in tumors were not related to response to therapy, 
furthermore, a low proliferative activity might be associated with improved pathological 
response (35). Another reports failed to observe a significant change in Ki-67 expression in 
paired samples before and after primary chemotherapy, though high Ki-67 expression was 
associated with pathological response (38). Some studies have focused on the evaluation 
of early changes in cell proliferation during treatment, by analyzing Ki-67 index in repeat 
tumor samples taken at variable time-points during chemotherapy (29,31,39,40). The 
clinical relevance of the modulation in Ki-67 expression are inconsistent; a significant fall 
in Ki-67 was seen 24-48 h following chemotherapy, but these changes was not related to 
clinical response (29,31) and disease outcome (29). Further, decrease in proliferation frac-
tion of more than 25% gave the best predictive value after the first course of chemotherapy 
(39), and absolute and percentage change in Ki-67 in first 21 days from baseline level, 
were only significant in responders but not in non-responder patients (40). A more recent 
study reported that neither pre- nor post-treatment median Ki-67 index nor median AI at 
different time points differed significantly between clinical or pathological responders or 
non-responders, and also found that the initial reduction in Ki-67 index was often followed 
by a rebound increase in cellular proliferation by the time of surgery; besides, there was no 
consistent pattern of changes in apoptosis throughout treatment (41). Taking into account 
all these inconclusive results, especially related to the clinical relevance of  the expression 
pattern of both apoptosis and proliferation in tumor cells, and their modulation which might 
be elicited by chemotherapy, an index based on the Ki-67 – apoptosis ratio could be of more 
importance. Though it is clear that this cannot accurately reflect the tumor growth dynam-
ics, this may have utility as an surrogate marker of response to treatment (24).  
Over-expression of bcl-2, an antiapoptotic protein, has been reported in up to 70% of all 
cases of breast cancer and was usually related with relatively indolent tumor cells due to 
association with markers of favorable prognosis in breast cancer patients. As far as the 
bcl-2 expression concerned in relation to the effect of primary chemotherapy, in some 
reports it was not observed a change in bcl-2 expression levels in paired tumor samples 
before and after chemotherapy (28,34,42); it was also noted the inverse relationship to 
apoptotic index but that was not retained after chemotherapy (34) and, with no relation to 
objective response. However, absence of bcl-2 expression in pre-chemotherapy specimens 
was associated with more frequent complete pathological response (42), as documented 
by others (30) who also observed an early decrease in bcl-2 expression on 14 days after 
commencing the treatment. Other studies only examined pre-chemotherapy bcl-2 levels 
and subsequent response to chemotherapy. Key pilot study by Ellis et al (28) showed 
that bcl-2 levels were lower in patients with clinical complete response, and others have 
shown that the absence of detectable bcl-2 predicted a better pathological response (43). 
On the contrary, it was reported that bcl-2 expression did not predict the ultimate clinical 
and pathological responses in either responding or non-responding tumors, but high rates 
of apoptosis and proliferation at baseline were associated with improved pathological 
response (44). So far, no firm conclusions can be made based on the articles studied.
A suggestion that the loss of p53 function is related to lower chemosensitivity has been 
extensively investigated. p53 mutation rates in breast cancer have been estimated between 
20 %- 40%, with some studies reaching up to 60%, depending on the methods used (14). 
Controversial data have been published as regard as the role of p53 in conferring increased 
resistance to chemotherapeutic agents. Some data from the literature revealed that the 
expression of p53 increases after chemotherapy (38,45) although it was not predicted to 
pathological response to treatment  A change in p53 protein expression in terms of reduction ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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in its expression after chemotherapy was observed in patients who has a clinically objec-
tive response but no changes in p53 expression was in non-responders (34).  Some other 
studies reported the opposite results; p53-negative expression in tumors correlated with a 
significant advantage towards better clinical and complete pathological response (46), and 
changes in p53 expression after treatment were mainly confined to p53-positive tumors at 
baseline, and it  was a significant predictor for poor clinical response (47). In another study 
it was shown that p53 positivity did not correlate to complete clinical response, but it was 
associated with higher risk of progression of disease and death (48). In addition, there were 
not observed significant changes in p53 expression pattern during or after chemotherapy, 
and no relevance to treatment response (43,44). Current clinical correlative studies on p53 
and chemosensitivity are mostly based in that they screen most TP53 gene alterations, point 
mutations, leading to the synthesis of a stable, and non-degradable protein that accumulates 
in tumor cells, and thus can be detected by means of immunohistochemistry (p53 protein 
overexpression). The use of different antibodies, staining standards, scores for positivity with 
different threshold values might be reason, at least in part, for less than optimal technique for 
determination of the p53 status. Additionally, with this method there is a risk of false negative 
cases related to the type of TP53 gene mutations; specific gene mutations encode unstable 
proteins, so they do not cause p53 overexpression detectable by IHC. Therefore, the method 
of DNA sequencing might be more sensitive to get reliable information of p53 status (49) but 
with this molecular biology methods complete gene should be sequenced because different 
p53 mutation sites may be associated with different functional implications.
Thus the integration of laboratory and clinical approaches into the search for reliability of   
mentioned biomarkers yield to no firm conclusions. Different chemotherapy regimens used, 
and definition of objective response, clinical versus pathological, might also contribute 
to the lack of concordance among reported results (1). Moreover, there is no standards 
method of assessing pathological response to primary chemotherapy in breast cancer 
patients (50) although patients who achieve pathologic complete response (7%-32 %) have 
a significantly better disease outcome than do those with residual disease. 
Selection bias related to different patients` selection criteria, clearly may influence the final 
results. Larger studies on population-based cohorts evaluating a panel of biomarkers are 
warranted, and ideally the studies should have prospective design.
Note
This work was supported by grant “Molecular biomarkers of breast cancer growth, inva-
siveness and metastasis: biological and clinical aspects” No 145018.
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